Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk (NVO) closed the most recent trading day at $50.29, moving +2.53% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 1.35%, ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021. What's ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The application is under expedited FDA review, with a decision expected within one to two ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Novo Nordisk NVO shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence. In early September, Novo ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...